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Abstract
Background: The aim of this study was to evaluate the diagnostic accuracy of positron emission
tomography (PET) using F18 fluorodeoxyglucose (FDG) in the differential diagnosis of early-onset
Alzheimer's disease (AD) and other dementias in a community-dwelling population.
Methods: A prospective sample of 102 individuals presenting consecutively to a primary care centre for
examination of suspected early-onset dementing diseases. The mean age of symptom onset of dementia in
our patients was 60.06 ± 4.28 years (mean ± 1SD, 95% lower confidence intervals (CI) 54.75, upper 63.37).
Patients were evaluated using standard clinical criteria for the diagnosis of dementia. Functional
neuroimaging data was obtained and nuclear medicine physicians blind to the clinical diagnosis generated
FDG-PET diagnoses. Final clinical diagnoses based on all available data were then established and compared
against PET diagnoses.
Results: Forty-nine patients received a final clinical diagnosis of early-stage AD (MMSE score 20.97 ±
5.10). There were 29 non-AD demented patients, 11 depressed patients and a miscellaneous group of 13
patients. Among patients with AD, the sensitivity and specificity of FDG-PET was 78% (95% CI: 66–90%)
and 81% (95% CI: 68–86%), respectively. The positive likelihood ratio (PLR) for a FDG-PET scan positive
for the diagnosis of AD was 4.11 (95% CI: 2.29–7.32) and negative likelihood ratio (NLR) for a negative
FDG-PET scan in the absence of AD was 0.27 (95% CI: 0.16–0.46). The pre-test probability was 48% and
post-test probability was 79.02%. The specificity of FDG-PET in the differential diagnosis of other
dementias, including frontotemporal dementia, was greater than 95%.
Recruitment methods in this study provide a sample that may be more representative of patients in the
general population and indicate that FDG-PET imaging can contribute to the diagnosis of AD in younger
adults with major increases in the positive likelihood rates and post-test probability.
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frontotemporal dementia and other forms of early-onset dementia.
Background
Clinical, pathologic, and genetic evidence indicates that
the various dementias have different underlying aetiolo-
gies and pathogenetic mechanisms. Treatment
approaches will therefore be different for each of these
conditions and accurate diagnosis is critical in order to
maximize the efficacy and appropriateness of specific
regimes. At present, precise differential diagnosis of
dementia relies on histopathological observations, only
available at autopsy. Thus, when faced with a patient with
a potential dementia condition, currently the clinician
must establish a probable diagnosis based on evidence
available from longitudinal clinical assessment, blood
tests, neuropsychological evaluation, and structural brain
imaging. Although in more advanced stages of dementia a
pre-mortem differential diagnosis typically becomes more
secure, accurate clinical diagnosis in the early stages con-
tinues to be difficult. Furthermore, with the prospect of
the introduction of pharmacological therapies that might
slow the rate of neurologic deterioration, dependence on
the progression of disease to a more advanced stage for
accurate diagnosis may subject patients to unnecessary
treatment delays. Establishing valid and reliable clinical
markers of dementia capable of identifying differential
pathognomonic change during the early clinical stages
and with young onset is required.
Early differential diagnosis and management of dementia
may benefit from precise functional neuroimaging infor-
mation. In disease states of the central nervous system
including dementia, the ability of neurons to take up
metabolites such as glucose is impaired. By identifying
regions of hypometabolism, functional neuroimaging
techniques, including positron emission tomography
(PET), can theoretically assist in the clinical evaluation
and differentiation of dementia syndromes [1-5].
PET and Dementia
A number of PET studies have identified distinct patterns
of brain metabolic abnormalities indicative of a disrup-
tion of neuronal function in individuals diagnosed with
various dementia syndromes, including Alzheimer's dis-
ease (AD) [6-8]; frontotemporal dementia (FTD([9-11];
vascular dementia (VD) [12]; primary progressive aphasia
(PPA) [13,14]; dementia with Lewy bodies (DLB) [15-17];
and depression [18,19]. PET studies are therefore increas-
ingly being used as an adjunct in the clinical evaluation of
patients with suspected dementia, particularly to aid in
early detection [1,17,20], or when a clinical diagnosis is
problematic [2,7,16,21,22]. However, the actual sensitiv-
ity and specificity of PET in the diagnosis of dementia in
young adults with the onset of dementia syndrome prior
to the age of 65 years is unclear.
Diagnostic Accuracy of PET
Multiple PET studies have shown that individuals diag-
nosed with AD demonstrate a characteristic pattern of glu-
cose hypometabolism, and the condition can be
distinguished from healthy controls with 93–94% sensi-
tivity and 93–99% specificity [23,24]). The capability of
PET to differentiate AD from other types of dementia is
more variable, with sensitivity values as high as 93–94%
[21,25] but as low as 44% [1], and specificity values rang-
ing from 63 to 80% [1,22,25].
While the majority of functional neuroimaging research
has focused on identifying AD, the sensitivity and specifi-
city of PET in diagnosing other dementia conditions has
also been investigated. PET distinguished FTD from AD or
DLB with 78% sensitivity and 71% specificity [3]. DLB has
been differentiated from AD with 85–90% sensitivity and
80–91% specificity [3,16,26].
Unfortunately, these studies of the diagnostic accuracy of
PET are fraught with a number of methodological limita-
tions. It is therefore difficult to assess the applicability of
the reported diagnostic values to routine practice [27,28].
Foremost, studies retrospectively recruited patients non-
consecutively from specialty clinics, often resulting in
cohorts composed entirely of individuals with manifest
dementia of one specific type [6,22,23,25,26]. This
method of recruitment resulted in homogeneous patient
samples that are not generally representative of those indi-
viduals who undergo dementia evaluations in primary
health care settings. Furthermore, when only those
patients who have tested positive on clinical grounds are
used to evaluate the accuracy of a diagnostic test, verifica-
tion bias can occur, leading to substantial bias in the esti-
mates of test performance [29]. To be more clinically
applicable, a study should include a spectrum patients
ranging from those at risk for a particular disease (such as
mild cognitive impairment) to those with manifest dis-
ease [30]. Assessing only a subset limits the clinical appli-
cability of the results. While no formal description of
patient recruitment was provided, one study appeared to
consecutively recruit its sample from a primary care centre
[1]. Not unexpectedly, this study reported PET diagnosedPage 2 of 9
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reported in those studies with homogeneous, retrospec-
tively selected sample populations.
Second, confidence of the results in a number of studies is
limited by small numbers of patients [1,3,16,21,26]. To
address the problems associated with small sample sizes,
two large, multi-centred studies have been conducted
[24,25]. However such a research design lacks standardi-
zation, and the lack of uniformity of procedures among
contributing sites for recruiting participants, collecting
clinical data, and recording and categorizing PET presents
a potentially significant confound [27].
Third, the highest diagnostic values have come from stud-
ies investigating the ability of PET to distinguish dementia
from healthy controls [23,24], while values generated
when differentiating amongst various dementia condi-
tions are generally lower and more variable [1,21,25]. The
highest sensitivity and specificity values may not therefore
generalize to clinical practice, where the clinician is often
faced with the difficult task of differentiating between
multiple potential conditions, rather than simply dissoci-
ating between manifest dementia and general good
health.
Finally, accuracy of PET diagnosis is frequently discussed
only in terms of sensitivity and specificity. Sensitivity
refers to the probability of a positive test among patients
with disease, while specificity refers to the probability of a
negative test among patients without disease. However,
clinicians don't generally know whether or not a patient
has disease, hence the need for ordering the test. Thus,
while sensitivity and specificity are among the most com-
monly reported methods for communicating the diagnos-
tic value of a particular test, they do not convey the
information needed to interpret test results. Ideally, one
would like to know what the probability of disease is
given a positive or negative test. For this, likelihood ratios
can be calculated to assess the likelihood of disease. The
positive likelihood ratio (PLR) indicates the increase in
probability of disease following a positive test, while the
negative likelihood ratio (NLR) represents the reduction
in probability of disease following a negative test result.
Aims of the Current Study
It is uncertain whether the diagnostic sensitivity and spe-
cificity of PET is suitably high enough to be of value in the
diagnosis of dementia. The aim of the current study was
therefore to evaluate the value of PET imaging in support-
ing the clinical diagnosis of common dementia syn-
dromes in a sample of individuals presenting
consecutively to a primary care centre for examination of
suspected neurological impairment in young adults. Such
a community-based case series is more representative of
the type of patients presenting for dementia investigation




All individuals referred to a young onset dementia clinic
for specialist neurologic investigation of suspected
dementia over the years from 1998 to 2006 were included
in the current study.
In Perth, Western Australia, patients suspected with early-
onset dementia are referred to the State referral centre
within the Neurosciences Unit, Department of Health,
Western Australia. Referral to this clinic is open to general
practitioners, neurologists, psychiatrists and other physi-
cians; patients and their families can self refer. A total of
102 consecutive community-dwelling patients with the
suspicion of early-onset dementia were entered into the
study. The clinical diagnoses of AD, FTD, DLB and PPA
were made using accepted criteria as previously published
[31]. This patient group represents a large proportion of
individuals with early-onset dementia in Perth, Western
Australia, as the majority are assessed and managed in this
clinic [31].
The cohort was composed of 102 consecutively presenting
patients, and included 55 males and 47 females. The
mean age of symptom onset of dementia in our patients
Table 1: Characteristics of the Patient Sample
Diagnostic Group Number 
(men/women)
Age at Symptom 
Onset*




Cohort 102 (55/47) 60.06 (4.28) 64.04 (8.90) 25 (5–30) 5.74 (2.75)
AD 49 (24/25) 61.75 (9.73) 65.65 (9.41) 20.97 (5.10) 5.34 (2.08)
FTD 17 (10/7) 59.87 (6.72) 63.42 (7.80) 25.44 (3.32) 5.19 (2.27)
DLB 6 (6/0) 64.47 (5.13) 69.19 (4.65) 27.40 (1.82) 6.68 (2.85)
PPA 6 (3/3) 61.18 (8.66) 67.54 (7.59) 21.00 (10.65) 7.28 (3.37)
Depress 11 (6/5) 53.02 (8.28) 56.29 (7.92) 27.11 (2.89) 5.34 (1.85)
Note: Depress = Depression. *Values are Means (SD). + Values are Medians (Range)Page 3 of 9
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(SD); 95% lower CI 54.75, upper 65.34) (Table 1).
Patients received a diagnosis based on standardized clini-
cal assessment [31] utilizing widely accepted diagnostic
criteria, including longitudinal clinical assessment, blood
tests, neuropsychological evaluation, EEG analysis, and
structural brain imaging [32-36].
The diagnosis of AD was based on the McKhan et al. [33]
and DSM-IV criteria[34], supported by neurological
examination, structural imaging in the form of MRI
(unless contraindicated in which case high resolution CT
scanning was performed), and supported by neuropsy-
chometry, blood investigations and EEG analysis. Simi-
larly, FTD and PPA were diagnosed using the criteria of
Neary et al. [35] and Mesulam [37,38], and supported by
neurological assessment, structural imaging, neuropsy-
chometry, blood analyses and EEG. DLBD using the McK-
eith criteria of 1996 [32] was used, supported by structural
imaging and other assessment as stated above. Depression
was diagnosed using DSM-IV criteria [34].
The clinical diagnostic information was not divulged prior
to PET scanning. The PET scans were analysed without
knowledge of the clinical diagnosis. The study design is
pictorially presented in Figure 1.
The research was performed with the approval of the Eth-
ics Committee of Graylands Selby Lemnos Hospital. The
research was carried out in compliance with the Helsinki
Declaration and subjects gave informed consent.
Final clinical diagnoses were: 49 patients with AD; 17
patients with FTD; 11 patients with depression; six
patients with DLB; six patients with PPA; and a miscella-
neous group of 13 patients (4 patients with other condi-
tions; 2 patients with mild cognitive impairment; 2
patients with vascular dementia; 2 patients with progres-
sive supranuclear palsy; 2 normal patients; and 1 patient
with corticobasal syndrome). The results of FDG-PET were
not included in the final clinical diagnoses. The PET diag-
noses were then compared with the final clinical diag-
noses.
Presenting complaints included cognitive decline
(85.29%), speech disturbance (8.82%), behavioural
change (4.90%), and gait abnormality (0.98%). Twenty-
eight patients (27.45%) self-reported a positive family
history of dementia.
The duration of follow-up for diagnostic classifications
used in the study were: AD = 5.35 years ± 1.31 (mean ± 1
SD); FTLD = 5.39 years ± 1.29; DLB = 5.25 years ± 1.35;
Depression = 5.89 years ± 1.52. The patients were seen in
regular follow-up throughout the study and this informa-
tion was always available.
PET Imaging and Data Analysis
Flurodeoxyglucose (FDG) was synthesised by automated
synthesis modules: IBA 18F-FDG Module with GE Tracer-
Lab Mx Module. All patients were imaged utilising an
Allegro GSO PET scanner (Philips Medical Systems).
Patients were instructed to fast for at least six hours, before
FDG administration weight and height was measured and
euglycaemia was confirmed. A standard patient dose
adjusted for surface area was given (Dose (MBq) = 370 ×
BSA(patient)/1.88). All patients were imaged at rest in a
quiet room with dim lights and minimal environmental
stimulation. A 45-minute uptake period following FDG
administration and prior to imaging was used.
Brain images were attenuation corrected using the 137Cs
attenuation source build into the Allegro camera system.
Scatter and random correction was performed as part of
the RAMLA-3D reconstruction algorithm as provided by
the camera manufacturer, Phillips.
Study Design FDG-PET in diagnosis of early-onset dementiaFigure 1
Study Design FDG-PET in diagnosis of early-onset dementia.
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BMC Neurology 2009, 9:41 http://www.biomedcentral.com/1471-2377/9/41The FDG PET images were reported off the Siemens work
stations following reorientation and windowing using the
Siemens "cool" colour scale. The intensity was adjusted
such that 'normal' brain, typically cerebellum or basal
ganglia was at the 100% level of the colour scale. Transax-
ial images were reconstructed using interactive reconstruc-
tion (3D-RAMLA) and measured transmission
attenuation correction. Functional data were analysed
semi-quantitatively using the Neurostat brain analysis
software package. Each study was transformed using lin-
ear scaling and non-linear warping to match the Neurostat
standard Talairach anatomical atlas. Maximum cortical
activity was extracted using the three-dimensional stereo-
tactic surface projection (3D-SSP) method described by
Minoshima et al., [39] and the data sets were normalized
to the average cerebral count for each patient.
The 3D-SSP images were compared individually with age-
appropriate and modality appropriate normal databases
generated in our PET centre using pixel-by-pixel 2 score
analysis. A statistically significant threshold, controlling
for multiple pixel comparisons and shape of the stochastic
process on 3D-SSP format, of Z = 4.53 (p < 0.05) was
used. The severity of the reductions in each of the lobes
was evaluated using volumes of interest analysis.
Normalisation of the SSP data was performed using glo-
bal cortical counts. If there was the impression of exten-
sive changes, the study was also normalised to cerebellum
or pons. After database normalisation the standard devia-
tion difference is shown as a colour scale to negative 7
standard deviations (Figure 2). The neurostat database
included age and sex matched normal controls as sup-
plied by Minoshima et al. [26].
Depending on the pattern of cerebral metabolism, each
case was classified as either: normal; possible AD – bipa-
rietal hypometabolism (asymmetric changes accepted)
with involvement of posterior cingulated and precuneus;
possible FTLD – frontal or frontal plus temporal hypome-
tabolism without parietal involvement – isolated tempo-
ral involvement considered possible temporal variant of
FTD; possible LBD – occipital pole involvement with pari-
etal ± frontal changes; possible PPA – predominantly
dominant hemisphere superior temporal and parietal
hympometabolism; or possible depression – bilateral
(asymmetric changes accepted) frontal or prefrontal
hypometabolism, with involvement of the anterior cingu-
late and basal ganglia.
Scans were reported by two experienced nuclear medicine
physicians and a consensus decision was reached.
Sample sizes in each of the diagnostic groups were quite
different; therefore, one-way analysis of variance could
not be used to evaluate MMSE performance across groups.
Case examples of AD, PPA, DLB and FTDFigur  2
Case examples of AD, PPA, DLB and FTD: (a) Neurostat SSP – Z score maps, using a negative (hypoperfusion) colour 
scale and global normalisation; and (b) transaxial, sagital and coronal slices, centred on the area of maximal abnormality.Page 5 of 9
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indicated there was no significant difference in MMSE per-
formance between individuals diagnosed with AD, FTD,
DLB, PPA or depression [F(4, 6.55) = 3.68, p = 0.07].
FDG PET data was evaluated in terms of the ability to dif-
ferentially diagnose the most common dementia syn-
dromes. Sensitivity and specificity values were calculated
by comparing the blind consensus diagnosis from the PET
scan against the consensus final clinical diagnosis. For all
values, a 95% confidence interval (CI) was calculated
according to the methods provided by Simel et al. [40].
Likelihood ratios (LR) were calculated according to the
general guidelines provided by Jaeschke et al. [41]. LR is
the likelihood that a given test result would be expected in
a patient with the target disorder compared to the likeli-
hood that the same result would be expected in a patient
without the disorder. An LR > 1 produces a post-test prob-
ability which is higher than the pre-test probability. An LR
< 1 post-test probability lower than pre-test probability.
When the pre-test probability is 30–70% test results with
a LR > 10 rule in disease. An LR < 1 produces a post-test
proability < pre-test probability. A very low LR (eg, < 0.1)




Of the 49 patients who received a final clinical diagnosis
of AD, the FDG-PET diagnosis correctly identified 38 of
these individuals, for a sensitivity of 78% (95% CI: 66–
90%). Of the 53 patients who received a final diagnosis
other than AD, the PET diagnosis correctly classified 43 of
these individuals as not having AD, for a specificity of
81% (95% CI: 68.86%). The positive LR for a FDG-PET
scan considered consistent with AD was 4.11 (95% CI:
2.29–7.32), suggesting an increase in the likelihood of a
final diagnosis of AD when diagnosed on FDG-PET with
AD. The negative LR for AD was 0.27 (95% CI: 0.16–
0.46), suggesting a more significant decrease in the likeli-
hood of a final diagnosis of AD when FDG-PET findings
are negative for AD. The pre-test probability prior to FDG-
PET scanning that the patient had AD was 48%. Following
FDG-PET scan the post-test probability was increased to
79.02% indicating that FDG-PET increases the diagnosis
probability of early-onset AD from 48% to 79.02%.
Other Dementia Syndromes
An analysis of the diagnostic accuracy of FDG-PET in
other forms of dementia was also performed (Table 2).
Unfortunately, the small number of patients in each diag-
nostic category limited the statistical confidence associ-
ated with the sensitivity results. However, these
preliminary findings indicated that the specificity of PET
for FTD, DLB, PPA, and depression was greater than 95%
Discussion
In a community-based series of early onset dementia, AD
was detected by FDG-PET with 78% sensitivity and 81%
specificity. The specificity is comparable with previously
reported values, while sensitivity was slightly lower
[21,25]. However, the current study group provides a sam-
ple of the general population, rather than the utilized in
most previous studies. Clinicians in primary care settings
can therefore take greater confidence from the findings of
the current study, which demonstrates a significant
increase or decrease in the likelihood of AD depending on
whether PET is consistent with or not suggestive of AD.
We argue that FDG-PET is especially useful in younger
patients with the suspicion of dementia. The high specifi-
city of FDG-PET in AD, FTD and LBD implies that a nega-
tive, or normal scan, in the presence of the suspicion of
dementia makes a dementia diagnosis very unlikely – in
our experience excluded. In younger patients where there
is a young spouse, children of teenager years or younger,
the diagnostic pressure to strive for a quick and accurate
diagnosis is high. Issues in relation to employment, insur-
ance and superannuation must be dealt with. We have
had experiences in our clinic where young patients (50 &
52 years) had been diagnosed with AD in other centres.
This diagnosis has been called into question and after
comprehensive clinical evaluation in our Centre, the diag-
nosis of dementia was excluded and supported by nega-
tive, or normal, FDG-PET scan. We have also seen patients
(48 & 53 years) who were told by other clinicians that
dementia does not occur in young adults. After a thorough
clinical assessment, the patients had a profile commensu-
rate with AD. Their FDG-PET scans were diagnostic. We
strongly believe, and supported by our observations com-
municated here, that FDG-PET is an essential component
of the diagnostic work-up of early-onset dementia. The
case is less compelling for older adults (> 80 years) with
the question of dementia where the impact of the diagno-
Table 2: Diagnostic Accuracy of PET in other forms of 
Dementia
Condition N Sensitivity Specificity
















Note: Values in parenthesis represent 95% confidence intervalsPage 6 of 9
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situations we might resort to FDG-PET.
Cognitive status as measured by the MMSE was equivalent
across the AD and non-AD dementia groups, and the
patients were considered similar in terms of disease sever-
ity. Differential FDG-PET diagnoses therefore cannot be
interpreted as simply reflecting differences in severity of
disease. Rather, functional disturbances in AD appear suf-
ficiently characteristic to allow FDG-PET to be beneficial
in differential diagnosis.
With the introduction of disease modifying agents that
might delay cognitive decline and maintain functional
level, accurate and early diagnosis of dementia is a critical
component of care. Based on performance on the MMSE,
our patients with AD were considered to be in a relatively
mild clinical stage. The current results clearly suggest
FDG-PET can contribute in the differential diagnosis of
AD in its early phases. This functional technique can
therefore be recommended to not only support the diag-
nosis of dementia, but hasten accurate diagnosis.
Unfortunately the small number of patients in additional
diagnostic categories limits the statistical confidence asso-
ciated with analysis of the sensitivity and specificity of
FDG-PET in identifying non-AD dementia syndromes.
However, the diagnostic specificity of FDG-PET was
exceptional in all the subgroups analysed. None of the 17
non-demented patients were misdiagnosed as having AD
or a non-AD dementia, indicating the chance of a healthy
patient being misdiagnosed with FDG-PET as having a
young onset dementia syndrome is substantially unlikely.
FDG-PET scanning therefore appears to be highly useful
in ruling out potential dementia syndromes, and impor-
tant clinical value in atypical or uncertain cases.
In the entire patient population 3.23% of all FDG-PET
scans were normal or non-specific. For each diagnostic
category the percentages of normal or negative scans were:
22.3% for AD (11/49); 47.0% for FTD (8/17); 33% for
LBD (2/6); 50% for PPA (3/6); and 81.8% for depression
(9/11). The normal or non-specific scans account for the
insensitivity of FDG-PET observed in our study. There
were almost no misclassifications of the FDG-PET scans as
they were read independently by highly trained nuclear
medicine physicians; if there was disagreement, consen-
sus was reached. We had no situations where FDG-PET
suggested a diagnosis divergent with the clinical assess-
ment. In our experience, a normal or non-specific FDG-
PET scan makes a dementing disease very unlikely.
In the current study, none of the patients diagnosed with
a dementing syndrome has undergone post-mortem con-
firmation of diagnosis. Rather, widely accepted diagnostic
criteria were used as the standard of reference for patient
diagnoses. Admittedly, there is the potential for discrep-
ancy between the clinical diagnosis and the true nature of
a dementia syndrome if pathological confirmation is not
obtained, and it is not possible to provide unequivocal
diagnostic accuracy data. However, even pathological
confirmation is not beyond reproach. There is no univer-
sally accepted set of pathological criteria, and the various
diagnostic algorithms place discordant degrees of reliance
on varying diagnostic factors [21]. Depending on the cri-
teria utilized, a patient may not always receive the same
autopsy diagnosis [42].
Conclusion
Attempts to differentiate potential dementia syndromes
based on clinical grounds alone can be difficult, particu-
larly when patients present with few or an atypical profile
of symptoms. In addition, clinical assessment typically
involves multiple examinations and tests over months
and years, which may lead to unnecessary delay in diagno-
sis and introduction of an appropriate treatment regime
should these become available.
Little more than a decade ago, the American Academy of
Neurology [43] regarded computed tomography and
magnetic resonance imaging as "optional" examinations
for the diagnosis and evaluation of dementia. However,
structural imaging techniques have now become a widely
accepted and highly valued component in the diagnosis
and management of dementia [44]. A similar paradigm
shift is underway with respect to the role of functional
imaging, as the contribution of rapidly evolving tech-
niques such as FDG-PET is becoming increasingly real-
ized. The current study takes another step forward in
validating the utility of functional imaging in the diagno-
sis of dementia, and suggests that in a clinical environ-
ment, PET may be an effective adjunct for the early
diagnosis and differentiation of various dementia syn-
dromes, especially in young adults, a conclusion sup-
ported by recent studies [45-47].
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